<DOC>
	<DOCNO>NCT02156726</DOCNO>
	<brief_summary>FCR ( fludarabine , cyclophosphamide , rituximab ) combination currently accept gold standard treatment young physically fit CLL patient . These excellent result , however , generally apply whole CLL population . This median age diagnosis CLL lie 65 72 year patient older 65 year fact account 50 % -75 % CLL population . Nevertheless , population considerably underrepresented large clinical trial CLL/SLL . Therefore , clear whether elderly/comorbid patient could profit new treatment approach purine analog combination chemoimmunotherapy . Several publication demonstrate unacceptable toxicity full-dose FC/FCR elderly CLL patient . However , regimens use attenuate dos fludarabine cyclophosphamide show promising efficacy low toxicity .</brief_summary>
	<brief_title>Observational Study Low Dose FCR Elderly/Comorbid CLL/SLL : The Q-lite Project</brief_title>
	<detailed_description>The objective observational study provide additional data confirm safety profile efficacy low dose FCR CLL patient treat clinical practice . Specific data interest : comorbid concitions , concomitant medication , CLL characteristic , prior treatment regimen , adverse event , reason discontinuation low dose FCR , overal response rate , complete response rate , progression-free survival , overall survival . This observational , non-interventional , medical record review study CLL patient . A total 200 patient CLL previously treat low dose FCR eligible study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>confirm diagnosis CLL SLL previously treat low dose FCR active disease require treatment per IWCLL criterion dose reduction fludarabine cyclophosphamide due age , comorbid condition , reduce creatinine clearance patient treat low dose FCR within prospective clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>fludarabine</keyword>
	<keyword>rituximab</keyword>
	<keyword>elderly</keyword>
	<keyword>comorbid</keyword>
	<keyword>FCR</keyword>
	<keyword>CIRS</keyword>
</DOC>